1 |
Lehmann-Horn F, Rudel R, Jurkat-Rott K. Non-dystrophic myotonias and periodic paralyses. In: Engel A, Franzini-Armstrong C, editors. Myology: basic and clinical. 3rd ed. New York: McGraw-Hill, 2004:1257-300.
|
2 |
Feero WG, Wang J, Barany F, Zhou J, Todorovic SM, Conwit R, et al. Hyperkalemic periodic paralysis: rapid molecular diagnosis and relationship of genotype to phenotype in 12 families. Neurology 1993; 43:668-73.
DOI
ScienceOn
|
3 |
Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics 2007;4:216-24.
DOI
ScienceOn
|
4 |
Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med 2008;40:665-71.
DOI
ScienceOn
|
5 |
Park YH, Kim JB. An atypical phenotype of hypokalemic periodic paralysis caused by a mutation in the sodium channel gene SCN4A. Korean J Pediatr 2010;53:909-12.
DOI
|
6 |
Ptacek L. The familial periodic paralyses and nondystrophic myotonias. Am J Med 1998;105:58-70.
DOI
ScienceOn
|
7 |
Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology 2004;63:1647-55.
DOI
ScienceOn
|
8 |
Kim JB, Kim MH, Lee SJ, Kim DJ, Lee BC. The Genotype and clinical phenotype of Korean patients with familial hypokalemic periodic paralysis. J Korean Med Sci 2007;22:946-51.
DOI
ScienceOn
|
9 |
Ricker K, Böhlen R, Rohkamm R. Different effectiveness of tocainide and hydrochlorothiazide in paramyotonia congenita with hyperkalemic episodic paralysis. Neurology 1983;33:1615-8.
DOI
|
10 |
Hantai D, Richard P, Koenig J, Eymard B. Congenital myasthenic syndromes. Curr Opin Neurol 2004;17:539-51.
DOI
ScienceOn
|
11 |
Brancati F, Valente EM, Davies NP, Sarkozy A, Sweeney MG, LoMonaco M, et al. Severe infantile hyperkalaemic periodic paralysis and paramyotonia congenita: broadening the clinical spectrum associated with the T704M mutation in SCN4A. J Neurol Neurosurg Psychiatry 2003;74:1339-41.
DOI
ScienceOn
|
12 |
Bouhours M, Luce S, Sternberg D, Willer JC, Fontaine B, Tabti N. A1152D mutation of the Na+ channel causes paramyotonia congenita and emphasizes the role of DIII/S4-S5 linker in fast inactivation. J Physiol 2005;565(Pt 2):415-27.
DOI
|
13 |
Okuda S, Kanda F, Nishimoto K, Sasaki R, Chihara K. Hyperkalemic periodic paralysis and paramyotonia congenita--a novel sodium channel mutation. J Neurol 2001;248:1003-4.
DOI
ScienceOn
|
14 |
Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999;79:1317-72.
DOI
|
15 |
Lehmann-Horn F, Rüdel R. Molecular pathophysiology of voltage-gated ion channels. Rev Physiol Biochem Pharmacol 1996;128:195-268.
|